Inoculum Effect with Cefazolin among Clinical Isolates of Methicillin-Susceptible Staphylococcus aureus: Frequency and Possible Cause of Cefazolin Treatment Failure
暂无分享,去创建一个
V. Fowler | Kavindra V. Singh | B. Murray | G. Corey | T. Rude | M. Stryjewski | E. Nannini | A. Bourgogne | K. Singh | Kavindra V. Singh | G. Corey | Tom H. Rude | Barbara E. Murray
[1] V. Fowler,et al. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[2] Lisa Saiman,et al. Endocarditis and Intravascular Infections , 2008 .
[3] L. Szczech,et al. Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[4] V. Fowler,et al. Telavancin versus Standard Therapy for Treatment of Complicated Skin and Skin Structure Infections Caused by Gram-Positive Bacteria: FAST 2 Study , 2006, Antimicrobial Agents and Chemotherapy.
[5] Robin Patel,et al. Lack of association of Staphylococcus aureus type A beta-lactamase with cefazolin combined with antimicrobial spacer placement prosthetic joint infection treatment failure. , 2006, Diagnostic microbiology and infectious disease.
[6] David R. Snydman,et al. Staphylococcus aureus Native Valve Infective Endocarditis: Report of 566 Episodes From the International Collaboration on Endocarditis Merged DatabaseMiro JM, and the International Collaboration on Endocarditis Merged Database Study Group (Univ of Barcelona; et al) Clin Infect Dis 41:507–514, 2005§ , 2006 .
[7] Bruno Hoen,et al. Staphylococcus aureus native valve infective endocarditis: report of 566 episodes from the International Collaboration on Endocarditis Merged Database. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[8] M. Fernández-Guerrero,et al. Cefazolin therapy for Staphylococcus aureus bacteremia. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[9] Kavindra V. Singh,et al. Relapse of type A beta-lactamase-producing Staphylococcus aureus native valve endocarditis during cefazolin therapy: revisiting the issue. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[10] K. Wilson. Preparation of Genomic DNA from Bacteria , 2001, Current protocols in molecular biology.
[11] R. Kumar. Preparation of genomic DNA from bacteria , 2001 .
[12] Mary Jane Ferraro,et al. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : approved standard , 2000 .
[13] D. Kernodle,et al. Characterization of a Chromosomal Gene Encoding Type B β-Lactamase in Phage Group II Isolates ofStaphylococcus aureus , 1998, Antimicrobial Agents and Chemotherapy.
[14] G. Weinstock,et al. In vivo testing of an Enterococcus faecalis efaA mutant and use of efaA homologs for species identification. , 1998, FEMS immunology and medical microbiology.
[15] G. Weinstock,et al. Repetitive Sequence-Based PCR versus Pulsed-Field Gel Electrophoresis for Typing of Enterococcus faecalis at the Subspecies Level , 1998, Journal of Clinical Microbiology.
[16] C. Stratton,et al. Association of Borderline Oxacillin-Susceptible Strains of Staphylococcus aureus with Surgical Wound Infections , 1998, Journal of Clinical Microbiology.
[17] D. Kernodle,et al. Structure-function relationships among wild-type variants of Staphylococcus aureus beta-lactamase: importance of amino acids 128 and 216 , 1996, Journal of bacteriology.
[18] A. Bisno,et al. Antibiotic treatment of adults with infective endocarditis due to streptococci, enterococci, staphylococci, and HACEK microorganisms. American Heart Association. , 1995, JAMA.
[19] T. Nishino,et al. Role of β-lactamase of methicillin-susceptible Staphylococcus aureus in resistance to first-generation oral cephems both in vitro and in vivo , 1994 .
[20] C. Stratton,et al. Characterization of four beta-lactamases produced by Staphylococcus aureus , 1992, Antimicrobial Agents and Chemotherapy.
[21] C. Stratton,et al. Use of extracts versus whole-cell bacterial suspensions in the identification of Staphylococcus aureus beta-lactamase variants , 1990, Antimicrobial Agents and Chemotherapy.
[22] D. Classen,et al. Failure of cephalosporins to prevent Staphylococcus aureus surgical wound infections. , 1990, JAMA.
[23] C. Stratton,et al. Differentiation of beta-lactamase variants of Staphylococcus aureus by substrate hydrolysis profiles. , 1989, The Journal of infectious diseases.
[24] W. Bruns,et al. Extracellular and membrane-bound beta lactamase of Staphylococcus aureus: their importance for the expression of penicillin resistance. , 1987, Journal of medical microbiology.
[25] Rosdahl Vt. Penicillinase production in Staphylococcus aureus strains of clinical importance. , 1986 .
[26] V. Rosdahl. Penicillinase production in Staphylococcus aureus strains of clinical importance. , 1986, Danish medical bulletin.
[27] R. Gustilo,et al. Bone and serum concentrations of five cephalosporin drugs. Relevance to prophylaxis and treatment in orthopedic surgery. , 1983, Clinical orthopaedics and related research.
[28] John E. Bennett,et al. Principles and practice of infectious diseases. Vols 1 and 2. , 1979 .
[29] R. Bryant,et al. Unsuccessful treatment of staphylococcal endocarditis with cefazolin. , 1977, JAMA.
[30] M. Richmond. Immunological techniques for studying beta-lactamases. , 1975, Methods in enzymology.
[31] D. Pohlod,et al. Clinical experiences with cefazolin and other cephalosporins in bacterial endocarditis. , 1973, The Journal of infectious diseases.
[32] J. Gold,et al. Experience with cefazolin: an overall summary of pharmacologic and clinical trials in man. , 1973, The Journal of infectious diseases.